Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 412

1.

Botulinum toxin type A in combination with standard urotherapy for children with dysfunctional voiding.

Petronijevic V, Lazovic M, Vlajkovic M, Slavkovic A, Golubovic E, Miljkovic P.

J Urol. 2007 Dec;178(6):2599-602; discussion 2602-3. Epub 2007 Oct 22.

PMID:
17945299
2.

The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.

Franco I, Landau-Dyer L, Isom-Batz G, Collett T, Reda EF.

J Urol. 2007 Oct;178(4 Pt 2):1775-9; discussion 1779-80. Epub 2007 Aug 17.

PMID:
17707430
3.

Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children.

Vanderbrink BA, Gitlin J, Toro S, Palmer LS.

J Urol. 2009 Feb;181(2):817-22; discussion 822. doi: 10.1016/j.juro.2008.10.045. Epub 2008 Dec 24.

PMID:
19110267
4.

Management of abnormal postvoid residual urine in children with dysfunctional voiding.

Kibar Y, Piskin M, Irkilata HC, Aydur E, Gok F, Dayanc M.

Urology. 2010 Jun;75(6):1472-5. doi: 10.1016/j.urology.2009.09.008. Epub 2009 Nov 6.

PMID:
19896172
6.

Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study.

Yucel S, Akkaya E, Guntekin E, Kukul E, Akman S, Melikoglu M, Baykara M.

J Urol. 2005 Oct;174(4 Pt 2):1612-5; discussion 1615.

PMID:
16148665
7.

Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder.

Mokhless I, Gaafar S, Fouda K, Shafik M, Assem A.

J Urol. 2006 Oct;176(4 Pt 2):1767-70; discussion 1770.

PMID:
16945643
8.

Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder.

Neel KF, Soliman S, Salem M, Seida M, Al-Hazmi H, Khatab A.

J Urol. 2007 Dec;178(6):2593-7; discussion 2597-8. Epub 2007 Oct 22.

PMID:
17945300
9.

Breaking the vicious circle: Onabotulinum toxin A in children with therapy-refractory dysfunctional voiding.

't Hoen LA, van den Hoek J, Wolffenbuttel KP, van der Toorn F, Scheepe JR.

J Pediatr Urol. 2015 Jun;11(3):119.e1-6. doi: 10.1016/j.jpurol.2014.10.006. Epub 2015 Feb 25.

PMID:
25794865
10.

Botulinum toxin as a new therapy option for voiding disorders: current state of the art.

Leippold T, Reitz A, Schurch B.

Eur Urol. 2003 Aug;44(2):165-74. Review.

PMID:
12875934
11.
12.

Long-term efficacy and durability of botulinum-A toxin for refractory dysfunctional voiding in children.

Vricella GJ, Campigotto M, Coplen DE, Traxel EJ, Austin PF.

J Urol. 2014 May;191(5 Suppl):1586-91. doi: 10.1016/j.juro.2013.10.034. Epub 2014 Mar 26.

PMID:
24679879
13.

Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance.

Tsai SJ, Ying TH, Huang YH, Cheng JW, Bih LI, Lew HL.

Arch Phys Med Rehabil. 2009 May;90(5):832-6. doi: 10.1016/j.apmr.2008.10.023.

PMID:
19406304
14.

Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.

Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, St├╝rzebecher B, Miller K, Knispel HH.

Eur Urol. 2005 Dec;48(6):984-90; discussion 990. Epub 2005 Jul 18.

PMID:
16126328
15.

Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder.

Schulte-Baukloh H, Michael T, St├╝rzebecher B, Knispel HH.

Eur Urol. 2003 Jul;44(1):139-43.

PMID:
12814690
16.

Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B.

J Urol. 2006 Jul;176(1):177-85.

PMID:
16753396
17.

Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.

Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J.

J Urol. 2007 Mar;177(3):1011-4.

PMID:
17296399
18.

Improved uroflow parameters and post-void residual following biofeedback therapy in pediatric patients with dysfunctional voiding does not correspond to outcome.

Nelson JD, Cooper CS, Boyt MA, Hawtrey CE, Austin JC.

J Urol. 2004 Oct;172(4 Pt 2):1653-6; discussion 1656.

PMID:
15371783
19.

Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.

Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH, Akbari HR, Nejat F.

Urology. 2006 Nov;68(5):1091-6; discussion 1096-7.

PMID:
17113899
20.

Correlation between uroflowmetry parameters and treatment outcome in children with dysfunctional voiding.

Vesna Z, Milica L, Marina V, Andjelka S, Lidija D.

J Pediatr Urol. 2010 Aug;6(4):396-402. doi: 10.1016/j.jpurol.2009.09.013. Epub 2009 Oct 21.

PMID:
19850529

Supplemental Content

Support Center